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ABSTRACT 
Biotechnology as a science includes various aspects of the management and manipulation of 
biological systems. Recent advances in immunology, molecular biology, cell culture and other associated 
areas provide an opportunity for scientists to move biology out of the laboratory and into the realms of 
society. This has many implications which mankind on a whole may not be prepared to cope with at this 
time. This new capability has been referred to as "Biotechnology". Biotechnology has also been defined 
as "the integrated use of biochemistry, microbiology, and chemical engineering in order to achieve the 
capacities of microbes and culture cells". Genetic engineering which includes gene splicing and recom- 
binant DNA-cloning is an exanlple of a recent offshoot of biotechnology. 
Because of the advent of biotechnology, one can now think of the prospect of engineering tomorrows 
vaccines. In the past, vaccine development has been laborious and in many instances an unrewarding task. 
After years of effort only a handful of safe, effective vaccines have emerged. In the biotechnology arena, 
new methodologies and strategies for immunizing humans and domestic animals against infectious 
diseases are providing new hope for discovering successful vaccines. While most of the effort in the past 
has focused on viral vaccine development, attention is now being directed towards vaccines for protection 
against parasitic diseases. 
Currently, considerable effort is being made to develop vaccines for malaria, coccidiosis (in fowl), 
cholera, malaria, schistosomiasis and trypanosomiasis among others. 
INTRODUCTION 
Since the discovery of the double helix 
configuration of the DNA molecule in 1953 
and the creation of the first chirema in 1973 
by use of genetic engineering techniques in 
San Francisco, something akin to a miracle 
has occurred between these two dates: 
Humans had found a way to decipher, write, 
spell and even correct the genetic mistakes of 
life itself. Today in many university labora- 
tories, students learn to manipulate the 
molecules of heredity with the same ease as 
they tinker with the desktop computer1. 
In many industrial and university 
laboratories, scientists are attempting to in- 
duce various species of microorganisms to 
produce materials they would not normally 
secrete as well as use as nourishment substan- 
ces such as petroleum, noxious wastes and to 
secrete endotoxin which could be used as 
potential control substances for arthro- 
pods which transmit infectious or- 
ganisms192'3. Biotechnology utilizes the 
expertise of specialists such as biologists, 
microbiologists, engineers, geneticists, 
biochemists, parasitologists, botanists among 
others who are exploring the mechanisms that 
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control and regulate most life forms on this 
planet. This effort will in the long run have 
incalculable consequences for the diagnosis 
and treatment of many of the world's most 
dreaded diseases such as cancer, heart 
problems, genetic deficiencies, malaria, 
cholera, schistosomiasis and leishmaniasis, 
as well as an improvement in the cultivation 
of plant species used to feed human and 
domestic animal populations. 
Is this new science a revolution or a 
renaissance ? Scientists have for many 
decades used microorganisms to ferment 
food and drink and produce antibodies. In 
addition they have produced hybrid plants2. 
Biotechnology as a science includes 
various aspects of the management and 
manipulation of biological systems. Recent 
advances in immunology, molecular biology, 
cell culture and other associated areas provide 
an opportunity for scientists to move biology 
out of the laboratory and into the realms of 
society. This has many implications which 
mankind on a whole may not be prepared to 
cope with at this time. This new capability has 
been referred to as "Biotechnology". Biotech- 
nology has also been defined as "the in- 
tegrated use of biochemistry, microbiology, 
and chemical engineering in order to achieve 
the capacities of microbes and culture cells". 
Genetic engineering which includes gene 
splicing and recombinant DNA-cloning is an 
example of a recent offshoot of biotechnolo- 
In reality, biotechnology is not new: 
biology has been used for decades to produce 
urea, food, solvent for industrial purposes and 
ethanol for use as energy. What really is n e i  
about this so called new science is the 
methodologies which have been developed, 
the style of its approach and increased inter- 
action between the scientific community, the 
citizenry and politicians in general. This type 
of interaction has occurred because of the 
potential breakthroughs in science which are 
deemed to be of great significance to life on 
this planet. Some examples of these scientific 
advancements are, new developments of 
single cell edible protein; nitrogen-fixing 
plants; crops resistant to pests: species of 
bacteria which are used in waste-recycling, 
pollution control and as biological control 
agents; gene therapy to correct diseases such 
as sickle-cell anemia; genetic screening for 
the purpose of isolated genes responsible for 
birth defects; microbial production of insulin; 
the production of interferon and growth hor- 
mones as well as a general increase in our 
knowledge of the immunological processes 
for diseases such as cancer, malaria and schis- 
tosomiasis. It has been predicted that biotech- 
nology will have its yeatest impact on 
agriculture and health2" '6'7*8 
A dynamic and promising new area of 
biotechnology is genetic engineering whose 
techniques such as microinjection is one of 
many procedures available to scientists for 
use in studying the nature of genes. These 
techniques, first developed in university 
laboratories to promote basic biotechnology 
research, are increasingly being used to pro- 
vide longevity and healthier lives through 
increased food production and inovative 
treatment of such illneses as cancer, hemo- 
philia, cystic fibrosis and other birth defects 
9 
and diseases . 
In the area of agriculture genetic en- 
gineering has been used to create animals 
with higher meat to fat ratio than the conven- 
tional ones, plants when sprayed with certain 
bacteria inhibit frost and others which have 
built-in resistance to viral infections. Many 
new breakthroughs are in the offering con- 
cerning the future of agriculture. 
New industries have been created in 
which new natural substances are produced 
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by genetically altered bacteria. Some of the 
new natural substances are heat-liable en- 
zymes and proteins mass-production of in- 
sulin, newly "designed" antibiotics to 
specifically destroy cancer cells, viruses and 
9 bacteria . 
Gene therapy is now a reality, as a result 
of the technology of gene-splicing. The first 
human treated with gene-splicing therapy has 
now been reported and the future in this area 
of biotechnology looks promising for medical 
9 
science . 
The American government is expected 
to launch a massive effort designed to map 
and decode all of the estimated 100,000 
human genes. The project is expected to cost 
3 billion dollars and to run for nearly 15 years. 
The end result of this effort will be a detailed 
construction manual for the genome, and the 
entire enetic profile that defines us as a 8 
species . 
Major accomplishments have already 
been made in hybridoma research by utilizing 
immunology in a variety of ways; in cell 
cultures which provide cells of both animal 
and plant origins as direct sources of 
materials in protoplast fusion techniques as 
well as in a variety of other methods. Biotech- 
nology is rapidly becoming broader in scope 
by the use of a vast array of technological 
techniques which, of course, have contributed 
2 to the area of laboratory science . 
Because of the advance of biotechnolo- 
gy, one can now think of the prospect of en- 
gineering tomorrow's vaccines.In the past, 
vaccine development has been laborious and 
in many instances an unrewarding task. After 
years of effort only a handful of safe, effective 
vaccines have emerged. In the biotechnology 
arena, new methodologies and strategies for 
immunizing humans and domestic animals 
against infectious diseases are providing new 
hope for discovering successful vaccines. 
While most of the effort in the past has 
focused on viral vaccine development, atten- 
tion is now being directed towards vaccines 
10 for protection against parasitic diseases . 
Hybridoma technology, specifically 
monoclonal antibodies have provided scien- 
tists with the means to mount new attacks 
against a variety of parasitic diseases. These 
efforts include detection, treatment and 
prevention of various parasitic diseases. 
Currently, considerable effort is being made 
to develop vaccines for malaria, coccidiosis 
10 (in fowl), cholera and schistosomiasis . 
Diseases for which priority should be 
given for development of vaccines are: 
malaria, schistosomiasis, trypanosomiasis 
(African and American), leishmaniasis, 
filariasis, ascariasis, hookwoxms, amebiasis, 
toxoplasmosis, hydatidosis/cysticercosis and 
giardiasis. These priorities will of course be 
different from country to country. A partial 
assessment of funding priorities in vaccine 
development for some parasitic diseases is 
shown in Table 1. 
In addition, biotechnology can also be a 
powerful tool in developing certain control 
methodologies against disease transmitting 
vectors. An example of this is the use of 
genetic engineering to develop a recombinant 
bacterium to produce endoxin for use as an 
insecticide for controlling pests such as the 
mosquito larva. This application could also be 
applied to control the snail vectors for schis- 
tosomiasis. 
An example of combined industry, 
government and academic collaboration has 
been the recent announcement of a candidate 
malaria vaccine being synthesized. Con- 
tinued animal studies as well as clinical trials 
11 in man are planned or currently underway . 
Great concern has arisen concerning 
safety-hazards associated with biotechnol- 
ogy, especially recombinant DNA. To date, 
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no problems have been identified. However, 
strict vigilance should be maintained in the 
scientific and government communities, as 
well as by concerned public interest groups. 
A neat array of training will be needed 
for future generations as regards biotechnolo- 
gy in the coming decades. This will require 
careful planning by both those in the aca- 
demic area and those in government and 
private institutions who provide funds for this 
purpose. 
Proper scientific and governmental in- 
frastructures must also be established for 
coping with currently identified as well as 
unforeseen problems which may arise from 
this new science. 
Funding support should be clearly iden- 
tified and those areas of the most significant 
health importance prioritized. For the field of 
parasitology this is important, for many of 
these disease-causing organisms are more 
complicated and the diseases they cause quite 
intractable as compared to the single cell 
viruses and bacteria. 
To conclude, I have tried to set the stage 
for a more indepth look at specific discussions 
of various aspects of the biotechnology as- 
sociation as well as its with parasitosis by my 
colleagues who follow with their presenta- 
tions during this conference. 
Table 1. Assessment of Funding Priorities in Vaccine Development for Some Parasitic Diseases* 
Public health Current Feasibility of Current 
Diseases significance vaccine using biotechno- funding 
status logy in vaccine 
development 
Malaria High High Good High 
Leishmaninsis Medium None BRN Low 
Chagas disease Medium None BRN Low 
Toxoplasmosis Medium None BRN Low 
Amebiasis High Low BRN Low 
Giardiasis High Low BRN Low 
Filariasis High None BRN Medium 
Schistosomiasis High Moderate BRN Good 
Onchocerciasis High None BRN Good 
Priority 
for new 
funding 
High 
High 
Medium 
Low 
Low 
Low 
Low 
Good 
Good 
African trypano- 
somiasis Medium None BRN Fair Low 
* Abbreviations : BRN--basic research needed. 
Adapted from Pan American Health Organization (198 1) with updated assessment by author. 
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QUESTIONS AND ANSWERS : 
1. Question: Can you please tell us more about the forthcoming vaccine for Schistosoma 
Answer : The effort to develop a vaccine for schistosomiasis is being funded by the Agency for 
International Development (AID). This effort is centered in Egypt in collaboration with 
the U.S. Navy (NAMRU-3) and certain U.S. Universities. The budget is approximately 38 
million and is expected to take 10 years. The program is just beginning. 
2. Question: Biotechnology has the ability to change the "behaviour" of organisms. This could be useful 
if it supports our purpose, but c a i ~  also become dangerous if it does not serve our purpose 
and may even endanger human/domestic animals life. Can we prevent this danger from 
happening ? Please, I like your comment on this matter. 
Answer : Production of new organisms and changes in behaviour and developed characteristics can 
be dangerous and constitute a potential threat in both humans1 domestic animals. As 
mentioned in my presentation certain safeguards such as monitoring of the use of any of 
these changes or new organisms should occur. It is very important that concerned citizens 
groups be involved in the same manner as they monitor the environment. The government 
of countries should be also involved in a constructed manner. 
3. Question: Concerning the goal of engineering tomorrow's vaccine, in parasitic diseases seems to be 
quite a big problem (most still need basic research). Why ? I wonder whether the strategy 
would force a sort of "short cut", in certain parasites, or not at all ? 
Answer : Basic research is needed in order to develop the necessary tools to prepare a schistosomiasis 
vaccine. The schistosomes are multiple celled organisms. Because of this the basic 
immunology approaches may be quite different from those used for single celled organisms 
such as malaria, bacteria and viruses. 
